Amgen releases Prolia study results
Prolia, administered as a single subcutaneous injection of 60mg once every six months, specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone).
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.
The Phase III 48-week clinical trial evaluating the non-inferiority of Elvitegravir versus Raltegravir each administered with a background regimen in HIV-infected treatment-experienced adults with HIV RNA (viral load)
The result of the study suggested that the economic model evaluated patients in Canada who were treated with Dabigatran Etexilate compared to those treated with warfarin in both